These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 7736526

  • 1. Antibody-directed enzyme prodrug therapy (ADEPT). A three-phase study in ovarian tumor xenografts.
    Sharma SK, Boden JA, Springer CJ, Burke PJ, Bagshawe KD.
    Cell Biophys; 1994; 24-25():219-28. PubMed ID: 7736526
    [Abstract] [Full Text] [Related]

  • 2. Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy.
    Sharma SK, Bagshawe KD, Burke PJ, Boden JA, Rogers GT, Springer CJ, Melton RG, Sherwood RF.
    Cancer; 1994 Feb 01; 73(3 Suppl):1114-20. PubMed ID: 8306255
    [Abstract] [Full Text] [Related]

  • 3. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
    Blakey DC, Davies DH, Dowell RI, East SJ, Burke PJ, Sharma SK, Springer CJ, Mauger AB, Melton RG.
    Br J Cancer; 1995 Nov 01; 72(5):1083-8. PubMed ID: 7577451
    [Abstract] [Full Text] [Related]

  • 4. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft.
    Stribbling SM, Martin J, Pedley RB, Boden JA, Sharma SK, Springer CJ.
    Cancer Chemother Pharmacol; 1997 Nov 01; 40(4):277-84. PubMed ID: 9225945
    [Abstract] [Full Text] [Related]

  • 5. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug.
    Blakey DC, Valcaccia BE, East S, Wright AF, Boyle FT, Springer CJ, Burke PJ, Melton RG, Bagshawe KD.
    Cell Biophys; 1993 Nov 01; 22(1-3):1-8. PubMed ID: 7889535
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
    Pedley RB, Sharma SK, Boxer GM, Boden R, Stribbling SM, Davies L, Springer CJ, Begent RH.
    Cancer Res; 1999 Aug 15; 59(16):3998-4003. PubMed ID: 10463598
    [Abstract] [Full Text] [Related]

  • 7. Antibody directed enzyme prodrug therapy (ADEPT): a three phase system.
    Sharma SK, Bagshawe KD, Springer CJ, Burke PJ, Rogers GT, Boden JA, Antoniw P, Melton RG, Sherwood RF.
    Dis Markers; 1991 Aug 15; 9(3-4):225-31. PubMed ID: 1813212
    [Abstract] [Full Text] [Related]

  • 8. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material.
    Webley SD, Francis RJ, Pedley RB, Sharma SK, Begent RH, Hartley JA, Hochhauser D.
    Br J Cancer; 2001 Jun 15; 84(12):1671-6. PubMed ID: 11401322
    [Abstract] [Full Text] [Related]

  • 9. Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.
    Rogers GT, Burke PJ, Sharma SK, Koodie R, Boden JA.
    Br J Cancer; 1995 Dec 15; 72(6):1357-63. PubMed ID: 8519645
    [Abstract] [Full Text] [Related]

  • 10. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.
    Blakey DC, Burke PJ, Davies DH, Dowell RI, East SJ, Eckersley KP, Fitton JE, McDaid J, Melton RG, Niculescu-Duvaz IA, Pinder PE, Sharma SK, Wright AF, Springer CJ.
    Cancer Res; 1996 Jul 15; 56(14):3287-92. PubMed ID: 8764123
    [Abstract] [Full Text] [Related]

  • 11. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein.
    Bhatia J, Sharma SK, Chester KA, Pedley RB, Boden RW, Read DA, Boxer GM, Michael NP, Begent RH.
    Int J Cancer; 2000 Feb 15; 85(4):571-7. PubMed ID: 10699932
    [Abstract] [Full Text] [Related]

  • 12. Analysis of antibody-enzyme conjugate clearance by investigation of prodrug and active drug in an ADEPT clinical study.
    Springer CJ, Poon GK, Sharma SK, Bagshawe KD.
    Cell Biophys; 1994 Feb 15; 24-25():193-207. PubMed ID: 7736524
    [Abstract] [Full Text] [Related]

  • 13. Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial.
    Sharma SK, Bagshawe KD, Melton RG, Sherwood RF.
    Cell Biophys; 1992 Feb 15; 21(1-3):109-20. PubMed ID: 1285323
    [Abstract] [Full Text] [Related]

  • 14. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
    Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J, Stribbling SM, Cushen N, O'Malley D, Begent RH.
    Clin Cancer Res; 2000 Mar 15; 6(3):765-72. PubMed ID: 10741695
    [Abstract] [Full Text] [Related]

  • 15. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185.
    Eccles SA, Court WJ, Box GA, Dean CJ, Melton RG, Springer CJ.
    Cancer Res; 1994 Oct 01; 54(19):5171-7. PubMed ID: 7923136
    [Abstract] [Full Text] [Related]

  • 16. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds.
    Springer CJ, Bagshawe KD, Sharma SK, Searle F, Boden JA, Antoniw P, Burke PJ, Rogers GT, Sherwood RF, Melton RG.
    Eur J Cancer; 1991 Oct 01; 27(11):1361-6. PubMed ID: 1835849
    [Abstract] [Full Text] [Related]

  • 17. Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model.
    Sharma SK, Bagshawe KD, Burke PJ, Boden RW, Rogers GT.
    Br J Cancer; 1990 May 01; 61(5):659-62. PubMed ID: 2337503
    [Abstract] [Full Text] [Related]

  • 18. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.
    Sharma SK, Pedley RB, Bhatia J, Boxer GM, El-Emir E, Qureshi U, Tolner B, Lowe H, Michael NP, Minton N, Begent RH, Chester KA.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):814-25. PubMed ID: 15701872
    [Abstract] [Full Text] [Related]

  • 19. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
    Houba PH, Boven E, van der Meulen-Muileman IH, Leenders RG, Scheeren JW, Pinedo HM, Haisma HJ.
    Int J Cancer; 2001 Feb 15; 91(4):550-4. PubMed ID: 11251980
    [Abstract] [Full Text] [Related]

  • 20. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours.
    Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O'Malley D, Tsiompanou E, Shahbakhti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, Begent RH.
    Br J Cancer; 2002 Sep 09; 87(6):600-7. PubMed ID: 12237768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.